glp-1 obesity drug news today sep 30 2025 Agonists Weight Loss Drugs Market Report, 2025-2030 The GLP-1 Access Gap: Mapping

A new era for weight loss

Novo-Nordisk A/S, Eli Lilly And Company, Sanofi, AstraZeneca, Pfizer Inc., Amgen, Inc., and Innovent Biologics, Inc

This means that FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed.

Here's what's happening and why it matters: GLP-1 receptors aren't just in your gut

Why GLP-1 Receptor Agonists Are Becoming Essential Cardiovascular Drugs Introduction Glucagon-like peptide-1 receptor agonists (GLP-1RAs)have emerged as a transformative class of medications in the management oftype 2 diabetes, demonstrating an approximate 14 percent reduction in major adverse cardiovascular events